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The formation and proliferation of protein aggregates play a central role in
a number of devastating neuro-degenerative diseases. Many experimental
studies indicate that the ability of existing aggregates to replicate is a key
property in generating their pathogenic effect across a range of diseases.
However, given the complexity of the process in vivo, no principled general
approach currently exists to obtain the rates of the fundamental steps that
underlie aggregate formation from measurements in living systems. In order
to address this challenge, here we present a general approach for analysing
aggregation kinetics that considers broad classes of processes that can be
described by a family of scaling solutions. Our approach is not limited only
to fibrillar aggregates, but applies to any aggregate shape. We show that the
rates can reliably be extracted by fitting of a simple logistic function, even
from experimental data in living systems, and give a very general analytical
expression that relates the scaling of the exponential rate with monomer
concentration to the microscopic details of the underlying reaction. This
approach can thus be used to infer the microscopic mechanism driving the
aggregation process from macroscopic measurements in complex systems.
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Introduction
Protein aggregation is a phenomenon of broad biological and medical interest, not least
because of the central role of such aggregates in many, currently incurable, neurode-
generative diseases[1, 2]. Of particular importance in the context of disease are those
aggregates that are able to self-replicate through a multiplication process by which ex-
isting aggregates trigger the formation of additional aggregates[3, 4]. Such aggregates,
regardless of their associated disease, are often termed prion-like for this parallel to the
highly infectious protein aggregates that are the causative agent of prion diseases[5, 6, 7].
Obtaining detailed mechanistic knowledge of the processes that are responsible for
converting normally soluble proteins to their pathological aggregated states is a key
objective of many ongoing studies. Significant progress on establishing mechanisms of
aggregation of purified protein in vitro has been made in the last decades[3, 8], yet our
understanding of how these processes are modulated in living systems is lacking, a factor
further complicated by the difficulty of obtaining mechanistic information from in vivo
measurements and the fact that even the shape of the growing aggregates in vivo is often
not clearly established.
In recent decades, a multitude of molecular events have been proposed to govern
the aggregation of proteins in living systems[9, 10, 11, 12, 13, 14, 15, 16]. A common
drawback of many such molecular models is that the level of specificity, in terms of the
mechanistic assumptions explicitly and implicitly incorporated in many mathematical
models, is often difficult to support given the complex nature of in vivo experimental
data. The conclusions drawn can thus be very specific and as a result have not gained
wide recognition in the research community. In particular, specific assumptions about
the aggregate shape are often made and usual aggregates are assumed to be fibrillar and
their rates of growth and multiplication are assumed to be size-independent. At the
other end of the spectrum are purely phenomenological models, which describe the data
well and do not suffer from this over-fitting[17, 18, 19]. However, their fitted parameters
typically provide no mechanistic insights into the experimental system, and are merely a
means to quantify and interpolate measurements. An approach is therefore needed that
is at the same time general enough to not over-interpret noisy and sparse data and still
provides a clear molecular interpretation of its parameters[20, 6]. Here we develop such
an approach based on our experience of molecular models of aggregation in a multitude
of systems. In line with the prion-like nature of many neurodegenerative diseases, we
consider mainly those mechanisms that involve the self-replication of aggregates, meaning
that the formation of new aggregates happens predominantly by a pathway depending on
the presence of existing aggregates. We develop a general approach, that does not require
aggregates to be fibrillar and is applicable regardless of the shape of the aggregates, the
way in which they grow and the mechanism by which they multiply. We also discuss
robust experimentally accessible quantities, the general functional form of the kinetic
curves and the scaling of the exponential rate with monomer concentration, that can be
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used to determine which classes of mechanisms are consistent or not consistent with the
data (see Fig. 1).
Figure 1: Schematic of analysis pipeline. Measures of aggregate amounts over time
in organisms expressing different levels of monomeric protein give rise to aggregation
kinetics. Determination of rates of exponential replication and their dependence on the
monomer concentration give mechanistic insights.
Results and Discussion
The kinetics of the full reaction network underlying an aggregation process is commonly
described by a master equation, a set of differential equations that describe how the
concentration of aggregates of each size evolves over time[3]. We denote by f(t, j) the
concentration of aggregates of size j at time t and the general master equation takes the
form
df(t, j)
dt
= Ψj[{f(t, i)}i,m(t)] ∀j (1)
where {f(t, i)}i denotes the set of all f(t, j) and Ψj is any functional that may depend on
the concentrations of all different sizes of aggregate. The same formalism applies if there
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are several different species of the same size and in this case Ψj[·] is simply a functional
of all sizes and types of aggregates. The zeroth and first moments of the size distribution
are given by P (t) =
∑
j f(t, j) and M(t) =
∑
j jf(t, j). If we treat the monomer
concentration separately, i.e. f(t, 1) = m(t) and j ≥ 2, then the physical interpretation
of P (t) and M(t) is the total number concentration and total mass concentration of
aggregates, respectively. These quantities are of particular interest because they, as well
as their ratio, the average number of monomers per aggregate µ(t) = M(t)
P (t)
, are the most
readily accessible experimentally[8]. Using the master equation, differential equations
for these moments, and other quantities that can be expressed as linear combinations of
the f(t, j), can be derived and are of the general from
dY
dt
= F [{f(t, i)}i,m(t)] (2)
where Y (t) is any quantity, such as a P (t), that can be expressed as a linear combination
of the f(t, j) and, as above, {f(t, i)}i denotes the set of all f(t, j) and F [{f(t, i)}i,m(t)]
denotes a general functional that may depend on the concentrations of all different sizes
of aggregate.
These key observables, Y , may depend on the concentration of each aggregated species
in an arbitrarily complex manner. This general dependence on the concentration of ag-
gregates of different lengths results in a very difficult general problem. To make progress,
we therefore neglect reactions which are second order or higher in the aggregate concen-
trations. Since the diffusion coefficients and concentrations of the aggregated species are
usually smaller than that of the monomer, this is likely to be an accurate assumption and
has been found to hold in vitro. There are no specific requirements on what the nature
of the individual steps is and they can involve any number of monomeric species and
their rate can depend on the size of the aggregated species. It is important to note here
that this assumption holds for the aggregation of all known amyloid forming proteins in
vitro and in particular it applies to all common mechanisms of multiplication, such as
fragmentation or secondary nucleation[21, 22, 23, 24]. Interactions between two or more
aggregate species may be important for clustering of aggregates at higher concentrations,
but such interactions appear to not play a significant role in the kinetics of aggregate
formation in vitro and are very unlikely to be relevant at the aggregate concentrations
encountered in vivo, which are several orders of magnitude below those used in vitro.
Processes that actively sequester aggregates into large plaques or aggresomes in vivo are
again likely to be of first order with respect to the aggregate concentrations[25, 26]. So
while physically and biologically this is a relatively conservative assumption, it signif-
icantly simplifies the mathematics, as now the rates of change of any species have to
be linear in all the f(t, j). In the above equation Ψj[{f(t, i)}i,m(t)], and consequently
also F [{f(t, i)}i,m(t)], are thus linear functions of the f(t, j), although they are not
necessarily linear in m(t).
We now consider the case when the monomer concentration is constant, thus m(t) =
m0. This situation is a good approximation for early times also in closed systems where
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total protein mass is conserved[3, 27], and is likely representative of many situations in
open biological systems where the monomeric protein concentrations is kept constant by
homeostasis[20, 10]. Eq. (2) now becomes
dY
dt
=
∞∑
j=2
αjf(t, j) + α1 (3)
where the αi may depend on the monomer concentration.
A key observation here is that almost all processes depend on the presence of ag-
gregates, including processes that change the size of existing aggregates by addition or
removal of proteins and any processes that change the number of aggregates in a mul-
tiplication reaction, such as fragmentation or secondary nucleation. Only the formation
of aggregates directly from monomers, primary nucleation does not explicitly depend on
the concentration of existing aggregates.
Scaling of replication rate with monomer concentration
In most cases, the molecular processes that make up the different contributions to the
master equation fall exclusively into one of two categories: those that affect onlyM(t) and
those that affect only P (t)[23]. Processes that change only the size of existing aggregates
without changing their number, i.e. growth or shrinkage, fall into the first category1. By
contrast, process by which existing aggregates multiply or new aggregates are formed
directly from monomer generally fall into the category of processes that affect only P (t).
While some of these processes, such as primary nucleation, may convert some monomers
into aggregates, their contribution to M(t) is generally negligible, as the average size
of aggregates is much larger than the nucleus sizes. This classification is also evident
from the master equation and the definitions of P (t) and M(t). All processes commonly
observed for in vitro aggregation can be classified in this manner. However, in vivo
there may exist processes that completely remove large aggregates from the reaction
mixture, through exocytosis, autophagy and other mechanisms. Such processes likely
cannot be classified exclusively into affecting only P (t) or M(t). In the following we will
summarize under the term growth the processes that increase M(t) and under the term
multiplication the processes that increase P (t), with the exception of primary nucleation,
which is considered separately.
Very generally, the rate of growth and its monomer dependence can be different for
every aggregate size. Therefore, the general form for the rate of increase in mass M(t)
is given by
dM
dt
= kg
∑
j
g(j,m0)f(t, j) (4)
1shrinkage to a critical size below which the aggregates dissociate into monomers does result in a loss
of aggregates, however, as aggregates are generally much larger than these critical sizes, this process is
negligible
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where g(j,m0) describes the size dependent growth rate (including the reverse reaction,
depolymerisation). One interpretation of g is the number of growth competent sites on
an aggregate of size j, however, this description is also consistent with a growth rate
that depends on the size due to other factors. To simplify notation in the following
discussions we have also explicitly included a factor kg, which we refer to as the rate
constant of growth, so g accounts for the size and monomer dependence of the rate.2
In most cases the same species adds onto all sizes of aggregates and the reaction
order of this growth step with respect to the monomer concentration is 1, i.e. g(j,m0) =
g¯(j)m
ng
0 , with ng = 1. If growth processes are saturated, as can sometimes be seen at
particularly high monomer concentrations[23, 28], a lower reaction order, ng ≈ 0, can be
observed. A saturation of the growth process is unlikely in most in vivo situations as the
concentrations present in vivo are well below the concentrations at which saturation of
amyloid growth is generally observed in in vitro experiments [29, 30, 31, 32]. Reaction
orders of ng > 1 could in principle be observed if the species being added is oligomeric,
present at low concentrations and in equilibrium with monomer, but the authors are not
aware of evidence for such a mechanisms in a real system of protein aggregation.
In analogy to Eq. (4) above, the general form for the increase in the number of
aggregates is given by
dP
dt
= km
∑
j
σ(j,m0)f(t, j) (5)
These multiplication processes are also often classified into two categories, those whose
rate does depend on monomer concentration and those whose rate does not depend on
monomer concentration. For example, multiplication by secondary nucleation generally
yields higher reaction orders with respect to the monomer concentration[27, 21, 33],
whereas fragmentation is usually independent of the monomer concentration. 3 Nor-
mally one type of process dominates the aggregation reaction over a range of monomer
concentrations, but in rare cases a competition of two multiplication processes can be
observed[23]. Any such phenomenon of multiple processes competing can easily be in-
cluded in the σ(j,m0) in the above description. In addition to these multiplication
processes, a primary nucleation process can be included in the form of a term that de-
pends only on the monomer concentration and is independent of the f(t, j). However,
under conditions of constant monomer, primary nucleation is simply a source term and
in the presence of multiplication processes it will always become negligible as the late
time limit is approached, because the contribution of multiplication to the rate increases
2In the standard in vitro model of fibril elongation by monomer addition we would thus have
g(j,m0) = 2m0. Also note that in our earlier work[3, 27, 23] we generally use k+ to denote the
elongation rate of linear fibrils. We use here kg to emphasize that this is the rate constant of a general
growth reaction, not just linear elongation.
3Note that in our earlier work[3, 27, 23] we generally use k2 to denote the rate constant of secondary
nucleation and k− to denote the rate constant of fragmentation. They are here replaced by km to
emphasize that we consider more general multiplication reactions.
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with increasing aggregate concentration in a positive feedback loop.
The aim now is to use the general equations for dP (t)/dt and dM(t)/dt above to
determine an approximate general solution and its dependence on the concentration of
monomer, m0. We rewrite f(t, j) = P (t)ρ(t, j), where ρ(t, j) now denotes the normalised
size distribution to get
dM
dt
= kgP (t)
∑
j
g(j,m0)ρ(t, j)
dP
dt
= kmP (t)
∑
j
σ(j,m0)ρ(t, j) (6)
As ρ is now a normalised distribution, the sums in these expressions are expectation
values of the functions g and σ. In order to obtain a closed from expression, we approx-
imate the expectation value of a function by the function of the expectation value of its
argument, i.e. 〈g(j)〉 ≈ g(〈j〉). This approximation will be most accurate when the size
distribution has most of its probability mass close to its mean and when the g is close to
linear in j. The performance of this approximation is evaluated in a number of different
systems below. The expectation value 〈j〉 is simply the average length so can be replaced
by µ(t) = M(t)
P (t)
.
dM
dt
= kgP (t)g(µ(t),m0) (7)
dP
dt
= kmP (t)σ(µ(t),m0) (8)
Now in order to proceed and derive a general solution, we would like to remove the time-
dependence of the average length µ(t). In other words, we would like to consider a steady
state size-distribution (overall aggregate amounts may still vary). Such a steady state
size-distribution arises when, after an initial adjustment period, a single solution mode
dominates the system of ODEs that describes the size distribution kinetics. In turn, this
occurs when at least one mode undergoes exponential growth, leading to an exponen-
tially increasing aggregate mass. Indeed many systems show this exponential increase
under constant monomer and quickly approach such a time-invariant size distribution
after a period determined by initial conditions[34, 27]. It thus remains to establish the
general conditions under which exponential growth of f(t, j) emerges. We show in the
Appendix that a necessary condition for exponential increase is that there exists at least
one feedback term in the size distribution equations, such that larger aggregates gener-
ate smaller ones, for example through fragmentation or secondary nucleation. Given the
evidence that aggregates with and ability to self-replicate are the key aggregate species
in most aggregation-related disorders[7, 35, 36, 37], a multiplication step will likely be
present for most systems of interest.
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Therefore, a steady state size distribution is likely to be approached by a wide range of
systems, and under this assumption of steady state, the average length remains constant,
µ(t) = µ, and the moment equations can be solved to give
P (t) = P0e
(kmσ(µ,m0))t
M(t) =
kgg(µ,m0)
kmσ(µ,m0)
P0e
(kmσ(µ,m0))t (9)
where P0 = P (0) and the exponential rate is
κ = kmσ(µ,m0) (10)
In order for this to be self-consistent, we require µ = M(t)
P (t)
, which allows us to determine
µ.
µ =
kgg(µ,m0)
kmσ(µ,m0)
(11)
We note that the numerator represents the rate of growth, whereas the denominator
represents the rate of multiplication. Therefore, as κ depends on both rates, experimental
measurements of µ are needed to obtain estimates of the relative rates of growth and
multiplication. The scaling of the rate κ is defined as
γ =
d
log(m0)
(log(κ)) = m0
d log(σ(µ,m0)
dm0
(12)
so if the specific functions g and σ are known, µ can be calculated and thus the scaling
can be determined.
These expressions are still general and also apply in the presence of processes that
remove aggregates from the reaction. The key questions in the context of clearance
mechanisms, however, concern when they are sufficient to prevent run-away aggregation.
In the approach we present here, we consider systems in which the aggregate amounts
are exponentially increasing, and thus clearance is necessarily a less important process.
We therefore do not explicitly include clearance processes in the following discussion and
instead will present a detailed discussion of their effect in a separate work.
To summarise, under the basic assumptions that aggregation does not involve reac-
tions of more than one aggregate and the aggregate mass grows exponentially, simple
closed form expressions for the exponential rate and average aggregate size can be de-
rived, Eqs. (10) and (11). In the rare cases when the increase in mass is experimentally
observed to not be initially exponential, the kinetics of these systems may be governed
by processes other than growth-multiplication, such as the direct formation of aggregates
from monomer by primary nucleation, or effects of spatial transport (see later) may be
rate-limiting.
In the following, we will illustrate our approach by considering generalised descrip-
tions of growth and fragmentation, derive analytical solutions in the limiting cases, and
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use numerical integration of the master equations in the remaining regions to determine
the scaling and show that the values we obtain are consistent with the approximate
general expressions obtained in Eqs. (10) and (11).
Specific parametrisation of size dependences of growth and frag-
mentation
To illustrate how the moment equations described previously arise from the master equa-
tion, we consider growth by monomer addition with a generalised size dependence of the
rate, along with a generalised fragmentation process.
df(t, j)
dt
= kgm0 (g(j − 1)f(t, j − 1)− g(j)f(t, j))
+2
∞∑
i=j
k(i, j)f(t, i)− f(t, j)
j∑
i=1
k(j, i) (13)
where, as before, m0 is the monomer concentration, kg is the rate constants of growth,
g(j) describes the size-dependence of growth and k(i, j) is the fragmentation kernel. The
fragmentation term has been expressed in its most general form, where the fragmentation
of an aggregate of size i into an aggregate of size j is given by k(i, j), a rate constant
which in general depends both on i and j (the first argument being the size of the original
fibril, the second argument the size of one of the fragments.4) We assume that the
fragmentation into pieces that are too small to grow and dissociate instead is negligible.
The zeroeth and first moments of this distribution give the number concentration, P ,
and mass concentration, M , of aggregated material, thus
dP (t)
dt
=
∞∑
j=1
df(t, j)
dt
≈ km
∞∑
j=1
φ(j)f(t, j) (14)
dM(t)
dt
=
∞∑
j=1
j
df(t, j)
dt
= kgm0
∞∑
j=1
g(j)f(t, j) (15)
where in Eq. (14) the elongation term cancels (as expected because elongation does not
affect the number of aggregates) and in Eq. (15) the fragmentation term cancels (as
expected because fragmentation does not change the amount of aggregated material,
ignoring loss back to monomer due to fragmentation). The fragmentation term has been
simplified by defining
∑j
i=1 k(j, i) = kmφ(j). Note that although the moment equation
depends explicitly only on the sum
∑j
i=1 k(j, i), which is the rate at which an aggregate
4As fragmentation yields a piece of size j and another one of size i− j, we require k(i, j) = k(i, i− j).
This is reflected by the factor of 2 in the second line; an aggregate of size i can create an aggregate of
size j either by breaking off a piece of size j or one of size i− j.
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of size j fragments, the size distribution f(t, j) will depend on the full fragmentation
kernel, k(j, i).
The most notable difference to the case of linear polymerisation[3, 27] is that these
moment equations, (14) and (15), are not closed and still depend on the aggregate
size distribution f(t, j), making them very difficult to solve. In the special cases that
g(j) = j or g(j) = 1 and φ(j) = j or φ(j) = 1, the above equations are again closed and
straightforward to solve.
Aggregate growth
The rate of growth can, in general, depend on the size of the aggregate, which we
accounted for with the factors g(j,m0) above. While other factors may influence the
size-dependence of the rate of growth, we explore here specifically the change in the
number of growth-competent sites per aggregate due to its dimensionality. If all sizes
grow by addition of the same type of species, we can make the implicit dependence
of g on the monomer concentration explicit and replace g(j,m0) → mng0 g¯(j). For the
following example we assume the species that adds is monomeric and adds in an un-
saturated reaction, so ng = 1. In the case of linear aggregates, the number of growth
competent sites is independent of aggregate size, thus g¯(j) = 2 (for 2 growing ends) and∑
j g¯(j)f(t, j) = 2P (t) as encountered for linear polymerisation [3, 27].
However, as the dimensionality of an aggregate increases, for example from linear
to planar, the number of growth competent sites per aggregate will depend on the size
of the aggregate. One dimensional aggregates, i.e. fibrils, grow from the ends and
the number of growth competent sites per aggregate does not change with size. Two
dimensional aggregates by contrast can grow at any point along their edge hence the
number of growth competent sites scales as the circumference of the aggregate, (which is
proportional to number of monomers in the aggregate to the power of 1/2). To describe
the generalised behaviour here we introduce the dimensionality d, which is a number ≥ 1.
This formulation allows us to derive a general model, which is a continuous function of the
dimensionality. Intermediate values of d, e.g. 1.2 can account for slightly branched linear
aggregates. More generally, d can simply be considered as a parameter that encapsulates
the size dependence of the growth rate, due to any effect in which the rate depends on a
power of the size. An illustration of some possible geometries of growing aggregates and
their corresponding values of d is shown in Fig. 2.
The number of growth-competent sites of and aggregate of size j is related to its mass
as follows
g¯(j) = adj
(1−1/d) (16)
where d is the dimensionality and ad is a shape-dependent constant of proportionality.
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d=1 d=2
d=3 "d=   " ∞
monomer (functional)
aggregate (disease-state monomer)
Figure 2: Illustration of specific aggregate geometries. Our formalism can account
for a size-dependent growth rate through the parameter d. One property that gives rise
to a size-dependent growth rate is the dimensionality of the growing aggregate; linear
aggregates grow independent of the size (d = 1), whereas higher dimensional aggregates,
such as discs (d = 2) or spheres (d = 3) show a size dependent growth rate. The
mathematical limit of d→∞ corresponds to a direct conversion of functional monomer
to a disease state monomer, without aggregation.
The values of ad in some special cases are
= 2 for linear aggregates
ad = 2
√
pi for disc shaped aggregates
= 32/3(4pi)1/3 for spherical aggregates
In the following we will subsume ad into the elongation rate constant kg.
The limits of interest are d = 1 which gives
∑
j g¯(j)f(t, j) = P (t) and d→∞ which
gives
∑
j g¯(j)f(t, j) = M(t). Physically, a value of d = 1 corresponds to the linear
polymerisation regime, i.e. each aggregate adds mass to itself at a constant rate, in-
dependent of its size. This is the typical behaviour for amyloid fibrils, such as Aβ, in
vitro. Regarding intermediate values of d, a spherical aggregate would be described by
d = 3, but structures of a 3 dimensional, highly branched nature could, up to a certain
size, result in d > 3. The limit of d → ∞ represents a hypothetical case in which the
elongation rate of a single aggregate is proportional to its mass. Every monomer in the
aggregate converts more monomer into aggregate. In this limit any fragmentation pro-
cesses become irrelevant, in fact the very concept of separate aggregates is meaningless.
Physically this model describes the kinetics of a prion-like disease if it were merely due to
individual proteins changing their conformational state to a “prion-state”. Each one of
these “prion-state” proteins can convert more native proteins to their prion state in this
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exponential run away reaction. This is the hetero-dimer mechanism originally proposed
by Prusiner et al [5] to describe prion replication. It is crucial to point out that, phys-
ically, this is significantly different to a description involving aggregation: If aggregates
are formed, only a fraction of the aggregated (”prion-state”) proteins, specifically the
growth competent, accessible sites, can convert more soluble protein to its prion state.
Fragmentation
As fragmentation is independent of the monomer concentration, we replace σ(j,m0) →
σ¯(j). Eq. (14) depends on the entire size distribution, not just its moments, a fact
which originates from the general treatment of the fragmentation rate. The form of this
fragmentation kernel is in general unknown, so in order to advance with this description
an explicit assumption about the functional form of k(i, j) has to be made. Following
previous work [38], we assume that the probability of an aggregate of size j to fragment,
kmσ¯(j) =
∑j
i=1 k(j, i), is proportional to the aggregate size to some power α, σ¯(j) = j
α,
where α is referred to as the homogeneity index. Note that this merely constitutes
an assumption about the functional form of the fragmentation kernel and no specific
assumptions about the individual k(j, i) need to be made.
The exponent α describes the dependence of the fragmentation rate on the size of
the aggregate. The limits of interest are α = 1 which gives
∑
j σ¯(j)f(t, j) = M(t) and
α = 0 which gives
∑
j σ¯(j)f(t, j) = P (t). A value of α = 1 means the probability
of an aggregate to fragment is proportional to its size. Such a description emerges
in the case of linear polymerisation, assuming that an aggregate is equally likely to
break at any monomer-monomer connection. This scaling is expected to decrease as the
dimensionality of the aggregate increases (for non-linear aggregates, larger aggregates
require more bonds to be broken to fragment). In the limit of α = 0 each aggregate is
equally likely to fragment, regardless of its size. A value of α below 0 corresponds to
what is known as the shattering region[38], where small aggregates fragment explosively
fast, and was therefore not considered in this description.
Situations in which α > 1, i.e. where the probability per monomer to break increases
with aggregate size, could be envisioned when the fragmentation effects act on larger
scales than single bonds, for example when mechanical stress affects aggregates above a
certain size, such as aggregation under shaking.
Putting together the functional forms for g(j) = j1−1/d and φ(j) = jα we obtain the
moment equations
dP (t)
dt
= km
∞∑
j=1
jαf(t, j) (17)
dM(t)
dt
= kgm0
∞∑
j=1
j1−1/df(t, j) (18)
which we will now solve for some limiting cases.
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Solutions for limiting cases
In the case that α is chosen such that
∑
j f(t, j)kmj
α is a moment of the distribution
(e.g. α = 0 or α = 1) the explicit dependence of the moment equations on the individual
k(j, i) disappears. Similarly, Eq. (15) becomes an equation that depends only on the
moments, not the entire size distribution, in the case that d = 1 and the limit that
d → ∞. Therefore, there are 4 possible combinations of limiting cases, that yield a
closed, solvable system of moment equations, which will be discussed below (in the limit
of d→∞, any multiplication processes become negligible, hence the cases of α = 0 and
α = 1 are equivalent for d → ∞). The approximate scaling predicted by Eqs. (11) and
(12). As g(j,m0) = m0j
1−1/d and σ(j,m0) = jα we obtain
µ =
kgm0µ
1−1/d
kmµα
and thus µ =
(
kgm0
km
) 1
α+1/d
(19)
and thus
κ = km
(
kgm0
km
) α
α+1/d
(20)
Therefore the scaling is given by
γ =
α
α + 1/d
(21)
In the limiting cases this gives γ = 1 as d → ∞, γ = 1/2 for α = d = 1 and γ = 0 for
α = 0 and d = 1.
Linear growth and breakage (d = 1, α = 1): This is the case of linear polymerisation
with fragmentation proportional to the mass, which has been solved previously for a
closed system with monomer addition[21, 8]. The moment equations are
dP (t)
dt
= kmM(t) (22)
dM(t)
dt
= 2kgm0P (t) (23)
which admit as a solution
M(t) = M0 cosh(κt) + P0
√
2kgm0
km
sinh(κt)
P (t) = P0 cosh(κt) +M0
√
km
2kgm0
sinh(κt)
where the exponential rate parameter κ =
√
kgm0km, is the same as that obtained from
the expression in Eq. (10). In the long time limit the scaling is thus γ = 1/2 and
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the average length µ = M(t)
P (t)
=
√
2kgm0
km
, also consistent with the expression derived in
Eq. (11).
Size-independent multiplication (d = 1, α = 0): This is the case of linear poly-
merisation where each aggregate is equally likely to fragment, regardless of its size. The
moment equations are given by
dP (t)
dt
= kmP (t) (24)
dM(t)
dt
= kgm0P (t) (25)
which are solved by
P (t) = P0e
kmt
M(t) =
kgm0
km
P0e
kmt
where κ = kmf , µ =
kgm0
km
and γ = 0, all consistent with our general expressions.
High dimensional growth (d → ∞): This is the limit in which every converted
monomer converts more monomer, thus we also refer to this mechanism as direct confor-
mational conversion (such a mechanism was originally proposed by Prusiner as a model
for prion replication[5]). The distinction of separate aggregates becomes pointless and
hence so does a distinct treatment of nucleation or fragmentation (thus M(t) = P (t)
andkgm0 = km). There is only one moment equation:
dP (t)
dt
= kmP (t) (26)
which is solved by
P (t) = P0e
kmt (27)
giving a exponential rate of κ = km, an average length of µ = 1 (because there is no
aggregation so P (t) = M(t)) and γ = 1, all consistent with our general expressions.
In summary an increase in d leads to an increase in the contribution of elongation
to the scaling exponent, whereas a decrease in α leads to decrease of the contribution of
elongation to the scaling exponent, by decoupling fragmentation from elongation.
Numerical interpolation between limits
In order to estimate how the scaling exponent varies for values of d and α which do not
have an analytical solution, we numerically integrated the master equation describing
the fibril length distribution, Eq. (13). In this context a fourth order Runge-Kutta
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integration algorithm was employed, the time evolution of the fibril length distribution
was determined at 40 different d and α values, at 4 different monomer concentrations
each. In order to evaluate numerically Eq. (13), the full fragmentation Kernel k(j, i)
needs to be specified. Given that
∑j
i=1 k(j, i) = kmσ(j) = kmj
α is fixed by our definition
of the fragmentation homogeneity, we let k(j, i) = kmj
α/j, i.e. the production of a piece
of any size is of equal probability. As the master equation consists of infinitely many
differential equations, one equation for each fibril length, a cut-off has to be chosen in
order to make numerical integration possible. In this case it was chosen at a fibril length
of 50000. The average fibril length in all simulations remained well below that value,
suggesting that the cut-off does not influence the result of the integration.
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Figure 3: Scaling exponent in different limits. The scaling exponent, evaluated by
numerical integration of the moment Eqs. (17) and (18) for generalised growth and frag-
mentation, is shown for a number of different size dependences of growth and fragmen-
tation. The different limiting regimes are highlighted and schemes for the corresponding
mechanisms shown below. The approximate expression derived for the scaling, from
Eqs. (10), (11) and (12), yields a highly similar plot.
The full length distribution was then used to calculate the time evolution of fibril
number and fibril mass. These results were treated in the same manner as experimental
data would: an exponential was fitted to the time evolution of aggregate mass in order to
extract κ. The monomer dependence of the 4 values of κ at each d and α combination was
then used to determine the scaling γ. The resulting values are plotted in Fig. 3, which
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was smoothed by linear interpolation between adjacent points. The values chosen for
the parameters were km = 2 · 10−5 s−1 and kg = 108 s−1M−1, the kinetics were evaluated
at 4 different monomer concentrations, spanning an order of magnitude around 1nM.
To within error, the simulations agree with our general approximate scaling calculated
above, Eqs. (10), (11) and (12).
Factors limiting aggregation and late-time plateau behaviour
In any physical situation, exponential growth is only possible for a finite amount of time.
Indeed, the appearance of a plateau value is very common in all experimental systems,
and curves of aggregate concentrations over time are usually sigmoidal. The origin of this
plateau is easily explained by conservation of total protein mass in a closed system, such
as the aggregation of purified protein in a test tube[3, 27], but in more complex systems
and in vivo plateaus may also arise for a variety of other reasons[16, 39]. The aim of
this work is to determine the replication rate and mechanistic class of the aggregation
reaction, thus the initial exponential increase is most informative and the specifics of the
approach to the plateau are of little importance. In the context of the related diseases,
this exponentially increasing phase is also the most relevant as it is responsible for the
increase in the number of aggregated species by orders of magnitude. We therefore
propose to use a logistic function to fit experimental data in practice, Eq. (28), as it
recovers the initial exponential behaviour and allows for plateauing at late time.
M(t) = M∞
1
1 + e−κ(t−th)
(28)
where M∞ is the plateau value, κ is the replication rate as in Eq. (10) and th is the half
time, which contains information about the initial concentration of aggregates and the
primary nucleation rate, but which we do not explicitly link to the underlying microscopic
processes here.
Performance in experimental systems
To showcase the application of this approach we first use a well-controlled system ob-
tained by simulating data of the in vitro aggregation of Aβ42, and then discuss perfor-
mance for experimental data from a significantly more complex in vivo system below.
These artificial data were generated by numerical integration of the moment equations,
dP (t)
dt
= knm(t)
nc + k2m(t)
n2M(t) (29)
dM(t)
dt
= 2k+m(t)P (t) (30)
under conservation of mass (m(t)+M(t) = m0), which describe the formation of fibrillar
aggregates through a double nucleation mechanism. Primary nucleation generates new
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aggregates directly from monomer with a reaction order of nc = 2, secondary nucleation
generates new aggregates from monomers, on the surface of existing aggregates with
reaction order n2 = 2 and elongation proceeds by the addition of monomers to the ends
of fibrils as described by a single-step mechanism. This model and the rates constants
used are those obtained by Cohen et al.[21] from the analysis of the in vitro aggregation
of purified Aβ42 peptide, which is linked to Alzheimer’s disease. Note that the above
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Figure 4: Logistic fit to solution of moment equations. a The data to be fitted
(points) were generated by numerical integration of the moment equations for aggrega-
tion with primary and secondary nucleation, with parameters set to kn = 3·10−4 M−1s−1,
k+ = 3 · 106 M−1s−1, k2 = 104 M−2s−1 and nc = n2 = 2, at a range of initial monomer
concentrations. Logistic functions, Eq. (28), were then fitted to each kinetic curve indi-
vidually. b The exponential rates obtained from the fits in (a) (red points) compared
to the prediction of the exponential rate from Eq. (10), using the set values of the rate
constants k+ and k2 and the reaction order n2. c Fits of Eq. (28) to the infectivity in
prion infected mice measured by the Standard Scrapie Cell Assay from Mays et al. [40].
d Fits of Eq. (28) to post-mortem stereological counts of the number of neurofibrillary
tangles in the superior temporal sulcus of Alzheimer’s disease patients from Gomez-Isla
et al.[41].
moment equations contain a primary nucleation term, which we have not included in our
approach as it becomes negligible at late times. Therefore, our approximations break
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down when primary nucleation becomes the dominant generator of new aggregates, i.e.
when the majority of new aggregates is generated by primary nucleation, not multiplica-
tion. Given the rate constants used here, primary nucleation produces more aggregates
than secondary nucleation as long as M(t) ≤ 0.03 µM = Mcrit. Thus it always domi-
nates the initial trajectory for reactions starting from a purely monomeric sample, but
how quickly Mcrit is reached, i.e. when secondary nucleation takes over depends on the
monomer concentration. At lower monomer concentrations, primary nucleation domi-
nates for a larger portion of the time until completion of the reaction. Indeed, as can be
seen in Fig. 4a, the fits of the logistic equation are poorest at the lowest concentration.
Eq. (10) predicts an exponential rate of κ =
√
2k+k2m
n2+1
0 and a scaling of γ = 1.5, our
fits, Fig. 4, yield γ = 1.42 and, evaluated at 4 µM κ = 6 s−1 compared to κ = 7 s−1
from Eq. (10). Thus, the use of a logistic function is sufficient to account for the late
time plateau, in this case due to monomer depletion, and the fits match the aggregation
curves well even when there are additional primary nucleation processes. The rates and
scaling extracted in this way is consistent with the interpretation of these quantities in
terms of the underlying microscopic rate constants given in Eq. (10).
Equally, the same strategy can be applied to experimental data obtained in a complex
in vivo system, as we demonstrate using data of prion disease in mice in Fig. 4c and
Alzheimer’s disease in humans in Fig. 4c. The prion data were obtained from Mays et
al. [40] and show measurements of the concentration of the infectivity in heterozygous
Prnp+/− mice. In this system, mice expressing the PrP protein are inoculated intra-
cerebrally with a sample containing prions, infectious particles consisting mainly of an
aggregated from of PrP, which then trigger the aggregation of more PrP in the mouse.
Mice are taken at several timepoints after inoculation and measurements are performed
by homogenising their brains and determining its infectivity in a cell based assay. The
infectivity readout is a measure for the concentration of infectious units. We assume that
they constitute a subset of the aggregated species and therefore, under the assumption of
a steady state distribution, the time evolution of infectivity can be approximated by the
same functional form as that of the total aggregate concentration. We obtain κ = 0.1
days−1, which corresponds to the number of infectious units doubling approximately
every week.5
The data of Alzheimer’s disease are obtained from Gomez-Isla et al.[41] and constitute
post-mortem counts of the numbers of neurofibrillary tangles (NFT), the microscopically
visible deposits of aggregated tau protein, in individuals with Alzheimer’s disease. Since
there is no controlled initiation event in these data as there is in the mouse data, the
time axis denotes the number of years since onset of the symptoms. The choice of time
zero is only required to combine the data points from different patients and does not
5We show in detail how further measurements in mouse lines expressing different levels of PrP along,
with estimates of the average aggregate size, can be used to further dissect these rates and obtain
mechanistic conclusions in a separate work.
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affect our analysis as it can be compensated by th in Eq. (28), so does not affect the
value of κ. We find that κ = 0.2 years−1, two orders of magnitude slower than the rate
for prion disease in mice extracted above6
Limitations and possible future extensions
Spatial inhomogeneities in aggregation Spatial inhomogeneities are normally not
of relevance for in vitro experiments, but they can be important in some living systems.
If spatial variations need to be taken into account, meaning if spreading of aggregates
throughout space is slow enough to limit the overall rate, then a reaction-diffusion type
approach has to be employed instead[42, 43, 44] and the description we present here only
accounts for the local reaction, not the time evolution of the whole system.
Surfaces, co-factors and activated states In some systems, the presence of co-factors
or activated states is believed to be important in enabling monomeric proteins to add
to aggregates. There are two regimes one needs to consider here: (i) the activated state
is present in steady state and co-factor is present at constant concentration in excess.
In this case, conversion rates and co-factor concentrations can simply be subsumed into
the existing rate constants, and the functional form of the system is not affected. The
steady state assumption is generally a viable one, as aggregation in living system usually
proceeds on a timescale much slower than monomeric protein turnover. Low concentra-
tions of co-factor that limit rates could however be of importance, which leads us to the
second regime. (ii) the rate is limited by a lack of co-factor or activating surface. Such a
situation can be reflected in a decrease in the effective monomer dependence of the rates.
It has been extensively discussed in Meisl et al.[23] and Dear et al. [28] and is amenable
to the same approaches by simple replacing rate constants with effective rate constants.
Thus, in both regimes, the approach we develop here should be sufficient to describe the
kinetics.
More complex models In vitro, multiplication of aggregates normally only involves
reactions of aggregates, possible with monomers, while in vivo complex, indirect mech-
anisms have been proposed, for example aggregates induce an inflammatory response in
a cell, which indirectly triggers aggregate formation in another cell. Our approach also
works in the latter case, as long the assumptions of linearity in the f(t, j) are fulfilled.
For example, as long as the probability that one cell triggers aggregation elsewhere is
proportional to some function of the form
∑
j αjf(t, j), such as the total mass or total
number of aggregates, it does not matter whether in reality this multiplication is induced
via an inflammatory pathway.
6Again, a detailed analysis of several datasets on the accumulation of tau in Alzheimer’s disease is
provided in a separate work.
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Conclusions
In this paper we have developed expressions, Eqs. (10) and (11), that approximate well
the average aggregate size, the exponential rate of increase of aggregate quantities and
its scaling with monomer concentration in a very general, broad class of multiplication-
growth-type mechanisms. We moreover show that a logistic function is suitable for
extracting the exponential rate from experimental data and thus infer the general class
of mechanism that gave rise to the observed kinetics. The robust, general approach we
present here is key in obtaining mechanistic insights and avoid over-fitting in the often
noisy and sparse experimental data from complex living systems.
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Appendix
Stationarity of the size distribution
A key assumption in we make in order to solve Eqs. (7) and (8) is that the normalized
size distribution of biofilaments stays unchanged. This does not always hold, and in fact
requires that a feedback term exists in the kinetics, whereby a larger species generates
a smaller species. To see this we write the size distribution kinetic equations in matrix
form:
f˙(t) = Af(t) +α (31)
f(t) =

f(t, 2)
f(t, 3)
...
f(t, j)
...
 , (32)
whereα is a (constant) vector of constants reflecting the contribution of primary nucleation-
like reactions and any external fluxes to the rates of formation of filaments of each length.
Moreover, A is the matrix governing the linear relationships between the different fil-
aments. The general solution to this nonhomogeneous ODE system, with zero initial
condition, is given by:
f(t) = Ψ(t)
∫ t
0
Ψ−1(t′)αdt′, (33)
where Ψ is the matrix whose columns are the eigenvectors ofA. Now, where there are no
feedback terms from e.g. secondary nucleation or fragmentation, A is lower triangular:
A =

−µ1 − q1 0 0 0 · · ·
µ1 −µ2 − q2 0 0 · · ·
a3,1 µ2 −µ3 − q3 0 · · ·
a4,1 a4,2 µ3 −µ4 − q4 . . .
...
...
...
. . . . . .
 , (34)
where µi is the rate of monomer addition to fibrils of size i, and qi accounts for clearance
and dissociation. In such a matrix, the eigenvalues are simply the diagonal elements, all
of which are negative here. For distinct µi’s, each solution mode has the form:
z(t, j) = cj
(
1− e−(µj+qj)t) . (35)
Thus the modes individually tend rapidly toward (positive) limiting values, and a steady
state size distribution is never achieved. Note that since there are infinitely many µ,
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many of the eigenvalues will be very similar in value, leading to very similar eigenvectors.
The individual f(t, j) are constructed as sums and differences of the first j modes; they
therefore take much longer to reach their limiting values with increasing size than do the
individual modes.
This argument demonstrates that without feedback reaction steps to populate the up-
per triangular section of the matrix, a steady-state size distribution cannot be achieved.
It does not, however, demonstrate that their presence is a sufficient condition. To do
this, we must understand what such a distribution would result from. It essentially re-
quires that one of the solution modes become much larger than the others at late enough
time. This in turn requires that the largest eigenvalue is positive, since the resulting ex-
ponential growth of the associated mode will ensure its late-time dominance, no matter
how small the difference between the two largest eigenvalues (exponential behaviour is
guaranteed by linearity). Clearly, the timescale for attainment of steady-state is just the
difference in magnitude of these two largest eigenvalues.
Unfortunately, the characteristic polynomial of a non-triangular matrix is not well-
behaved as the dimension tends to infinity, due to sign changes. A different approach is
thus likely necessary. We note, however, that stationarity has been proved for secondary
nucleation and fragmentation with a size-independent elongation rate[34], given a size-
independent k+.
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